$SNEX

BEXIGA ANNABELLE G sold $171K of SNEX

BEXIGA ANNABELLE G sold 1,500 shares of StoneX Group Inc. (SNEX) at $113.92 ($0.17M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BEXIGA ANNABELLE G
Published Jul 17, 2026, 1:57 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 2:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SNEX
Neutral
high confidence
Mentioned
$SNEX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNEXNeutralLow
01

Why it matters

The disclosed event is an open-market sale by a director, with a stated pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

02

Market read

Traders may note the insider sale for sentiment, but there is no new fundamental catalyst in the text.

03

What to watch

The article does not include any concurrent buys, changes in other insiders, or new company disclosures, so the signal-to-noise for trading is low.

Relevance 3/10Novelty 3/10Timing: latest Form 4 filed 2026-07-16 for a 2026-07-15 sale

Background

The article is a SEC Form 4 insider transaction disclosure for StoneX Group Inc. (SNEX).

Company-level read

Ticker impact

$SNEXNeutralHigh confidence
Context

StoneX Group director BEXIGA ANNABELLE G sold 1,500 shares on 2026-07-15 at $113.92 via a 10b5-1 plan, per Form 4.

Expected impact

Likely minimal near-term price impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction, but it specifies a Rule 10b5-1 pre-arranged plan and provides no new operating, guidance, or regulatory information.

Market effects

No sector read-across; this is company-specific insider trading disclosure only.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • StoneX Group Inc.

    Company whose director insider sale is disclosed on Form 4.

  • BEXIGA ANNABELLE G

    Director who sold 1,500 shares at $113.92 on 2026-07-15 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WGOMedAI 8/10

Winnebago stock rises as StoneX lowers price target on industry outlook

StoneX lowered its price target on Winnebago (WGO) to $36 from $40, maintaining a Buy rating. The stock trades at $26.83 with a 5.62% dividend yield. Winnebago issued fiscal 2027 guidance for sales of $2.65B-$2.80B and adjusted EPS of $1.65-$2.25, with midpoints above consensus. The company reduced 2026 RV shipment expectations and guided 2027 shipments to 265,000-295,000 units. The stock rose 10.5% on Monday following earnings and guidance.

$MXLMed

MaxLinear stock rating reiterated at Buy by StoneX ahead of results

StoneX reiterated a Buy rating on MaxLinear (MXL) with a $125 price target ahead of its October 22 earnings report. The firm expects Q3 revenue of $215M-$220M, matching consensus. MXL shares are down 20% in a week but up 320% year-to-date. S&P upgraded its outlook to positive, citing strong infrastructure revenue growth. Analysts highlight MXL's potential in the optical market.

$EQBKMed

StoneX lowers Equity Bancshares stock price target on NIM outlook

StoneX reduced its price target for Equity Bancshares (EQBK) to $58 from $59, citing net interest margin expectations. The firm raised its fiscal 2026 EPS forecast to $5.18 but lowered the 2027 estimate to $5.27. EQBK's stock trades at a P/E ratio of 10.58, and analysts expect net income growth. The company recently reported Q3 earnings beating estimates, with EPS of $1.40 vs. $1.29 expected, but revenue missed slightly.